Currently, a phase II/III randomized trial is underway to evaluate the efficacy of margetuximab combined with retifanlimab (PD-1 antibody) (with or without chemotherapy) and margetuximab combined with tebotelimab (PD-1 antibody) in patients with HER2-positive GC or gastroesophageal junction cancer (45). This evidence concerns the gene ERBB2 and gastric cancer.